Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676)

Authors
de Vetten, MP Jansen, JH van der Reijden, BA Berger, MS Zijlmans, JMJM Lowenberg, B
Citation
Mp. De Vetten et al., Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676), BR J HAEM, 111(1), 2000, pp. 277-279
Citations number
9
Categorie Soggetti
Hematology,"Cardiovascular & Hematology Research
Journal title
BRITISH JOURNAL OF HAEMATOLOGY
ISSN journal
00071048 → ACNP
Volume
111
Issue
1
Year of publication
2000
Pages
277 - 279
Database
ISI
SICI code
0007-1048(200010)111:1<277:MROPAM>2.0.ZU;2-4
Abstract
The anti-CD33 monoclonal antibody linked to NAc-gamma calicheamicin gemtuzu mab ozogamicin (CMA-676) was used to treat a patient with Philadelphia/bcr- abl-positive acute myeloid leukaemia, We report a morphological and cytogen etic complete remission after treatment with two doses of gemtuzumab ozogam icin as a single agent, Using real-time polymerase chain reaction (PCR), ge mtuzumab ozogamicin treatment resulted in a 3-log tumour mass reduction in bone marrow.